Journals / Turkish Journal of Hematology / 2012 / Cilt: 29 - Sayı: 1

Hemato-onkolojide destek tedaviler: Son kılavuzlar ışığında gözden geçirme

Supportive care in hemato-oncology: A review in light of the latest guidelines

Pages
1–9
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Herein we present a review and brief summarization of some of the agents used for supportive care in cancer patients in light of the latest guidelines..

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Recent developments in cancer therapy have resulted in increases in treatment success rates and survival.
📊
Key Findings & Data:Additionally, there have been developments in supportive care, which seeks to ameliorate or minimize the negative effects of chemotherapy.
💡
Conclusion & Impact:Herein we present a review and brief summarization of some of the agents used for supportive care in cancer patients in light of the latest guidelines..
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Recent developments in cancer therapy have resulted in increases in treatment success rates and survival. One of the basic goals of such therapy is improving patient quality of life. Chemotherapy protocols for solid or hematological malignancies-most of which include multiple agents-negatively impact patient quality of life. Additionally, there have been developments in supportive care, which seeks to ameliorate or minimize the negative effects of chemotherapy. Herein we present a review and brief summarization of some of the agents used for supportive care in cancer patients in light of the latest guidelines..

Özet

Son yıllarda kanser tedavisi alanında sağlanan gelişmeler hastaların tedavi şanslarının artması ve yaşam sürelerinde uzama ile sonuçlanmıştır. Bu sıkıntılı tedavi sürecinde yaşam kalitesinin arttırılması temel hedeflerden biri olmalıdır.Solid ya da hematolojik maligniteler için verilen çoğu çoklu ajanlar içeren kemoterapi protokolleri hastaların yaşamkalitesini olumsuz etkiler. Bu olumsuz etkilerden hastayı kurtarmak ya da en az hasar görmesi sağlamak amacıyla yapılan destek tedavilerde de gelişmeler vardır. Bu derlemede, destek tedavi olarak verilen bu ajanlardan bazılarını en son kılavuzlar ışığında kısaca özetledik.

🔖

Cite This Article

GÜNDÜZ, E., GÜLBAŞ, Z. (2012). Hemato-onkolojide destek tedaviler: Son kılavuzlar ışığında gözden geçirme. Turkish Journal of Hematology, Cilt: 29 - Sayı: 1, 1–9. https://ajindex.com/articles/412606

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H: Chemotherapy-induced nausea and vomiting: Incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 2007
  2. 503 2.Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J: Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006
  3. 4478 3.Schwartzberg L: Chemotherapy-induced nausea and vomiting: state of the art 2006. J Support Oncol 2006
  4. 8 4.Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, du Bois A, Tonato M: Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenecity-an update. Support Care Cancer 2005
  5. 84 5.Baker PD, Morzorati SL, Ellet ML: The pathophysiology of chemotherapy-induced nausea and vomiting. Gastroenterol Nurs 2005
  6. 480 6.Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark- Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM: American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006
  7. 2947 7.NCCN Clinical practice guidelines in oncology
  8. v.2.2006: Antiemesis. National Comprehensive Cancer Network (NCCN), 2006 8.Navari RM: Antiemetic control: Toward a new standard of care for emetogenic chemotherapy. Expert Opin Pharmacother 2009
  9. 644 9.Navari RM: Pathogenesis-based treatment of chemotherapy- induced nausea and vomiting: Two new agents. J Support Oncol 2003
  10. 103 10.Hesketh PJ: New treatment options for chemotherapy- induced nausea and vomiting. Support Care Cancer 2004
  11. 554 11.Diemunsch P, Grelot L: Potential of substance P antagonists as antiemetics. Drugs 2000
  12. 546 12.The Italian Group for Antiemetic Research: Dexamethasone, granisetron or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995
  13. 5 13.Navari RM: Apprepitant: A neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 2004
  14. 724 14.Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996
  15. 96 15.Bymaster FP, Falcone JF, Bauzon D, Kennedy JS, Schenck K, DeLapp NW, Cohen ML: Potent antagonism of 5-HT3 and 5-HT6 receptors by